Trill Impact Ventures co-leads USD 25 million series B financing round in May Health
Advancing novel treatment for women suffering from Polycystic Ovary Syndrome related infertility.Trill Impact Ventures, announces that it together with Bpifrance, has co-led a USD 25m series B financing round in May Health, a French-American medical device company targeting Polycystic Ovary Syndrome (PCOS) related infertility. The round also saw participation from existing May Health investor Sofinnova Partners. Proceeds will advance the clinical development of May Health’s innovative device, as well as reaching CE marking that will enable market introduction in select European countries.